Chemical Property of Levocarnitine
Chemical Property:
- Appearance/Colour:white crystalline powder
- Melting Point:197-212 °C(lit.)
- Refractive Index:-32 ° (C=1, H2O)
- Boiling Point:287.5°C (rough estimate)
- PKA:3.80(at 25℃)
- PSA：60.36000
- Density:0.64 g/cm3
- LogP:-1.80650
- Storage Temp.:2-8°C
- Solubility.:H2O: 0.1 g/mL at 20 °C, clear, colorless
- Water Solubility.:2500 g/L (20 ºC)
- XLogP3:-0.2
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:3
- Exact Mass:161.10519334
- Heavy Atom Count:11
- Complexity:134
- Purity/Quality:
-
99% *data from raw suppliers
D-Carnitine *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi
- Statements:
36/37/38
- Safety Statements:
26-36-37/39
- MSDS Files:
-
SDS file from LookChem
Useful:
- Chemical Classes:Biological Agents -> Amino Acids and Derivatives
- Canonical SMILES:C[N+](C)(C)CC(CC(=O)[O-])O
- Isomeric SMILES:C[N+](C)(C)C[C@@H](CC(=O)[O-])O
- Recent ClinicalTrials:Levocarnitine To Protect the Liver From Chemotherapy for Leukemia or Lymphoma
- Recent EU Clinical Trials:Carnitine supplementation as a therapy to improve insulin sensitivity in Type 2 diabetic patients with low carnitine status
- Recent NIPH Clinical Trials:The effects of electrical stimulation for lower limbs to maintenance hemodialysis patients with frailty receiving carnitine: A pilot study
-
Role in Cellular Energy Metabolism
Levocarnitine is an essential component in cellular energy metabolism, contributing to the transport of fatty acids into the mitochondria for energy production.
-
Treatment for Valproic Acid Overdose
Levocarnitine, the active isomer of carnitine, has been utilized in the treatment of valproic acid overdose, including cases resulting from both overdose and regular dosages of valproic acid.
-
Bioavailability and Distribution
While a single dose of levocarnitine does not persist in the system for an extended period, chronic intravenous administration in hemodialysis patients can lead to significant uptake into tissues, with muscle carnitine levels increasing by up to 200%.
-
Effectiveness in Renal Anemia
Studies have shown that levocarnitine treatment can ameliorate renal anemia and reduce the requirements for erythropoiesis-stimulating agents (ESAs) in hemodialysis patients. Multiple studies support the efficacy of levocarnitine in treating renal anemia.
-
Beneficial Effects on Dyslipidemia
Levocarnitine supplementation may benefit dialysis patients with dyslipidemia by enhancing the transport of free fatty acids into mitochondria and reducing their availability for triglyceride synthesis.
-
Restoration of Carnitine Levels
Levocarnitine supplementation has been found to restore normal plasma carnitine levels and alleviate symptomatic deficiencies with good tolerability. In hemodialysis patients, it increases plasma carnitine concentrations and improves fatigue as assessed by patients.
